5Prystowsky EN, Benson DW Jr, Fuster V,et al, Management of patients with atrial fibrillation : a statement for healthcare professionals from the subcommittee on electrocardiography and eleetrophysiology, American Heart Association [ J ]. Circulation, 1996,93 ( 10 ) : 1262 - 1277.
6[3]Martha Mitch Funnell. Robert M. Anderson. The problem with compliance in diabetes. JAMA ,2000,284 ( 13 ): 1709.
7[6]Tebbi CK. Treatment compliance in childhood and adolescence. Cancer, 1993,71:3441.
8[7]Vaur L, Vaisse B, Genes N, et al. Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large - scale trial. Am J Hypertens, 1999,12 (4 Pt 1 ): 374-380.
9[8]Andrejak M,Genes N,Vaur L,et al. Electronic pill boxes in the evaluation of antihypertensive treatment compliance:Comparison of once daily versus twice daily regimen. Am J Hypertens,2000,13 (2) :184-190.
10[9]Van Berge Henegouwen MT. Van Driel HF. Kasteleijn Nolst Trenite DG. A patient diary as a tool to improve medicine compliance. PharmWorldSci. 1999, 21 (1): 21 -24.
6Committee on Infectious Diseases. Rabies-prevention policy update: new reduced-dose schedule [ J ]. Pediatrics,2011,127 (4) :785-787.
7Shantavasinkul P, Tantawichien T, Jaijaroensup W, et al. A 4-site, sin- gle-visit intradermal postexposure prophylaxis regimen for previously vaccinated patients : experiences with > 5000 patients [ J ]. Clin Infect Dis,2010,51 (9) :1070-1072.
8Liu H, Huang G, Tang Q, et al. The immunogenicity and safety of vac- cination with purified Vero cell rabies vaccine(PVRV) in China under a 2-1-1 regimen[ J]. Hum Vaccin ,2011,7 ( 2 ) : 121-124.
9Wongsaroj P, Udomchaisakul P, Tepsumethanon S, et al. Rabies neu- tralizing antibody after 2 intradermal doses on days 0 and 21 for pre- exposure prophylaxis[ J]. Vaccine ,2013,31 ( 13 ) : 1748-1751.
